The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: A population based study in Modena, Italy

References

• Beghi E, Chiò A, Couratier P, Esteban J, Hardiman O, Logroscino G, et al. The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. 2011;12:1–10.
   PubMed Web of Science ®Google Scholar
• Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
   PubMed Web of Science ®Google Scholar
• Radunovic A, Annane D, Jewitt K, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2009;4:CD004427.
   Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;3:CD001447.
   Google Scholar
• Ng L, Khan F, Mathers S. Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2009;4:CD007425.
   Google Scholar
• Katzberg HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2011;1:CD004030.
   Google Scholar
• Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial. Lancet Neurol. 2006;5:140–7.
   PubMed Web of Science ®Google Scholar
• Georgoulopoulou E, Vinceti M, Bonvicini F, Sola P, Goldoni CA, de Girolamo G, et al. Changing incidence and subtypes of ALS in Modena, Italy: a 10-years prospective study. Amyotroph Lateral Scler. 2011;12:451–7.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, Chio A, Couratier P, Mitchell JD, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008;79:6–11.
   PubMed Web of Science ®Google Scholar
• Chiò A, Calvo A, Moglia C, Mazzini L, Mora G; PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82:740–6.
   PubMed Web of Science ®Google Scholar
• Atsuta N, Watanabe H, Ito M, Tanaka F, Tamakoshi A, Nakano I, et al. Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2008;276:163–9.
   PubMedGoogle Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Rowland LP. Riluzole for the treatment of amyotrophic lateral sclerosis: too soon to tell?. N Engl J Med. 1994; 330:636–7.
   PubMed Web of Science ®Google Scholar
• Mitchell JD, O’Brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2006;7:67–71.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Mahon L, Hardiman O. Riluzole and prognosis in ALS: findings of the Irish ALS register over a five-year study period (1995 − 2000). Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2(Suppl 2):43–4.
   Google Scholar
• Brooks BR, Belden DS, Roelke K, Parnell J, Peper S, Houdek A, et al. Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) − motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:60–1.
   Google Scholar
• Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. The Kings’ Database 1999 − 2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(Suppl 2):43.
   Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Riluzole and amyotrophic lateral sclerosis survival: a population based study in southern Italy. Eur J Neurol. 2007;14:262–8.
   PubMed Web of Science ®Google Scholar
• EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis: Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS): revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996 − 2000. J Neurol Neurosurg Psychiatry. 2003;74: 1258–61.
   PubMed Web of Science ®Google Scholar
• Chio A, Bottacchi E, Buffa C,Mutani R,Mora G; PARALS. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948–50.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Lepore V, et al. ALS multidisciplinary clinic and survival: results from a population based study in southern Italy. J Neurol. 2007;254:1107–12.
   PubMed Web of Science ®Google Scholar
• Chiò A, Calvo A, Ghiglione P, Mazzini L, Mutani R, Mora G; PARALS. Tracheostomy in amyotrophic lateral sclerosis: a 10-year population based study in Italy. J Neurol Neurosurg Psychiatry. 2010;81:1141–3.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V; Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249:609–15.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• Chiò A, Canosa A, Gallo S, Cammarosano S, Moglia C, Fuda G, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population?. Neurology. 2011; 77:1432–7.
   PubMed Web of Science ®Google Scholar